Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

@inproceedings{Roberts2017TargetingBW,
  title={Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies},
  author={A Roberts and DCS Huang},
  booktitle={Clinical pharmacology and therapeutics},
  year={2017}
}
The intracellular protein B-cell-lymphoma-2 (BCL2) has been considered an attractive target for cancer therapy since the discovery of its function as a major promoter of cell survival (an anti-apoptotic) in the late 1980s. However, the challenges of targeting a protein-protein interaction delayed the discovery of fit-for-purpose molecules until the mid-2000s. Since then, a series of high affinity small organic molecules that inhibits the interaction of BCL2 with the apoptotic machinery, the so… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 80 references

results of a phase I study of navitoclax in patients with relapsed or refractory disease

  • Roberts, A. W. et al. Substantial susceptibility of chronic ly inhibition
  • J. Clin. Oncol. 30, 488–496
  • 2012
Highly Influential
11 Excerpts

Durable treatment-free remission and effective retreatment in patients with relapsed/refractory chronic lymphocytic leukemia who achieved a deep response with venetoclax combined with rituximab

  • D Brander
  • Haematologica 101,
  • 2016
Highly Influential
10 Excerpts

a multicentre, open-label, phase 2 study

  • Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chroni deletion
  • Lancet Oncol. 17, 768–778
  • 2016
Highly Influential
6 Excerpts

A phase 1 study of venetoclax (ABT-199 / GDC0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma

  • Gerecitano, J.F
  • Blood 126,
  • 2015
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…